Background
==========

Patients with asthma who are poorly controlled on inhaled corticosteroids are often prescribed long-acting beta-agonists \[[@B1],[@B2]\]. However, most asthmatics continue to need short acting beta-agonists for relief of breakthrough symptoms and for treatment during asthma exacerbations. Despite accumulating evidence that tolerance develops to the bronchodilator effects of beta-agonists, the effect of regular long-acting beta-agonists on the response to treatment of exacerbations is rarely considered in treatment guidelines.

Tolerance to the systemic \[[@B3]\] and bronchoprotective \[[@B4]\] effects of beta-agonists is known to occur during regular beta-agonist use. It was previously thought that tolerance to bronchodilation did not occur. However, recent studies have shown that tolerance to bronchodilation is easily demonstrated when tested from a bronchoconstricted state, such as after methacholine or exercise challenge \[[@B5]-[@B13]\]. Patients using regular long-acting beta-agonists may therefore be less responsive to further beta-agonist treatment during acute bronchoconstriction. This is potentially a serious problem for patients who are taking these drugs and experience an exacerbation of asthma.

Studies of bronchodilator tolerance have demonstrated that regular beta-agonist treatment impairs the bronchodilator response to moderate doses of up to 400 μg of salbutamol \[[@B5]-[@B12]\]. It has been suggested that this tolerance can easily be overcome by administering higher doses of beta-agonists, but this has never been formally examined \[[@B14]\]. Treatment of asthma exacerbations in emergency departments usually includes higher doses of beta-agonists given via a nebuliser, typically up to 5 mg salbutamol \[[@B1],[@B2]\]. There have been no randomised controlled trials of the effects of regular long-acting beta-agonists on this emergency treatment.

It is also unknown whether beta-agonist tolerance use affects the airway response to other bronchodilators. The anticholinergic bronchodilator ipratropium bromide is often added to emergency asthma treatment in severe bronchoconstriction and in those who respond poorly to beta-agonist alone \[[@B2],[@B15]\]. It is likely that the bronchodilator response to ipratropium is not affected by prior long-acting beta-agonist treatment since it acts via a different receptor. However, beta~2~-receptors and muscarinic cholinergic receptors share some intracellular secondary messengers and their signalling pathways may interact \[[@B16],[@B17]\]. Hence it is plausible that bronchodilator responsiveness to ipratropium could be affected by beta-agonist tolerance. Moreover, it is possible that beta-agonists have a non-specific effect on airway smooth muscle tone thereby altering the response to other bronchodilators regardless of intracellular signalling pathways \[[@B18],[@B19]\].

Given the role of high dose beta-agonist and ipratropium bromide in the management of asthma exacerbations, it is important to assess their effectiveness in the setting of long-acting beta-agonist treatment. We performed two studies to address the following questions:

Study 1: Does high dose salbutamol overcome the bronchodilator tolerance associated with regular long-acting beta-agonist use?

Study 2: Does beta-agonist bronchodilator tolerance affect the bronchodilator response to ipratropium bromide?

Methods
=======

Subjects
--------

Subjects had physician-diagnosed asthma with a provocative dose to cause a 20% fall in FEV~1~(PD~20~) less than 1.5 mg of methacholine (study 1) or less than 30 ml saline (study 2) at screening (see below). Subjects were not using long-acting beta-agonists prior to the study and had not changed their asthma medications nor had a respiratory tract infection for 6 weeks prior to study entry. The studies were approved by the Waikato Ethics Committee. All subjects provided written informed consent.

Study design
------------

Both studies were random-order, double-blind, cross-over studies comparing formoterol 12 μg twice daily with placebo. Randomisation was by computer-coded bottles of identical capsules for use with the Foradil Aeroliser (*Novartis, Auckland, New Zealand*). Additional beta-agonists were not allowed throughout the studies. Ipratropium was used for symptom relief.

Study 1: High-dose salbutamol
-----------------------------

This was a crossover study with 2 arms. Subjects inhaled formoterol or placebo twice daily for 1 week. Thirty-six hours after the last dose, subjects underwent a methacholine challenge and salbutamol response as described below. Subjects then crossed to the other medication for a repeat sequence of 1 week of treatment, methacholine challenge and salbutamol response.

Methacholine challenge was performed using a modified Yan technique \[[@B20]\]. Subjects inhaled doubling doses of nebulised methacholine until the FEV~1~had fallen by ≥ 20%. The PD~20~methacholine was calculated by linear interpolation of the last two doses. Immediately after completion of the methacholine challenge, subjects were given 5 mg salbutamol via a Sidestream nebuliser and System 22 aerosol mask (*Profile, Bognor Regis, UK*) powered by oxygen at a rate of 6 L/minute. FEV~1~was measured at 5, 10, 15 and 20 minutes after starting the nebuliser.

Study 2: Ipratropium bromide
----------------------------

This was a crossover study with four arms. For each arm subjects inhaled formoterol 12 μg or placebo twice daily for 1 week. Thirty-six hours after the last dose, subjects underwent a hypertonic saline challenge and bronchodilator response as described below. Subjects then received the alternative medication and started the next arm of the study. Two study arms compared the bronchodilator response to salbutamol after formoterol and placebo treatment and the other two arms compared the response to ipratropium bromide after formoterol and placebo.

Hypertonic saline challenge was performed according to the method of the European Respiratory Society \[[@B21]\]. Subjects inhaled 4.5% saline until the FEV~1~fell by ≥ 20%. The PD~20~saline was calculated by linear interpolation of the last two doses. Immediately after the challenge, 200 μg salbutamol or 40 μg ipratropium was given via a metered dose inhaler and large volume spacer. FEV~1~was measured 5, 10, 15, 20 and 30 minutes after the bronchodilator.

Analysis
--------

The main outcome measurement was the area under the salbutamol or ipratropium response curves (AUC), expressed as a percentage of the fall in FEV~1~induced by challenge. Comparisons between treatments were adjusted for baseline FEV~1~and dose of provocational agent given using analysis of covariance. A secondary outcome for each study was the final post-bronchodilator FEV~1~, which was also adjusted for the fall in FEV~1~during challenge. Post hoc comparisons between placebo and formoterol treatments were were made using Tukey\'s exact method. Comparisons of pre-challenge FEV~1~and of PD~20~were made using paired Student\'s t-tests. PD~20~values were log-transformed for analysis.

Previous studies indicated that a sample size of 12 subjects would detect a 30% fall in AUC with 80% power at α = 0.05 \[[@B5]\].

Results
=======

Study 1: High dose salbutamol
-----------------------------

Eleven subjects were recruited and completed the study. Baseline characteristics of the subjects are shown in table [1](#T1){ref-type="table"}. There was no significant effect of order of treatment on AUC, pre-challenge FEV~1~or PD~20~methacholine. The pre-challenge FEV~1~and PD~20~methacholine were not significantly different between placebo and formoterol arms (table [2](#T2){ref-type="table"}).

###### 

Baseline characteristics of subjects

  Study                                                               1\. High dose salbutamol   2\. Ipratropium
  ------------------------------------------------------------------- -------------------------- ------------------
  Number of subjects                                                  11                         11
  Male                                                                3                          3
  Age (range)                                                         37 (22 to 62)              34 (19 to 53)
  Number on inhaled steroids Dose range (μg)(budesonide equivalent)   9 (200 to 1200)            10 (200 to 2000)
  FEV~1~% predicted at screening (range)                              79 (61 to 101)             86 (65 to 103)

###### 

Results of the high dose salbutamol study (study 1)

  Treatment                                                                           Placebo                       Formoterol
  ----------------------------------------------------------------------------------- ----------------------------- -------------------
  Pre-challenge FEV~1~(L) (SD)                                                        2.55 (0.75)                   2.57 (0.72)
  Post challenge FEV~1~(L) (SD)                                                       1.92 (0.59)                   2.00 (0.51)
  PD~20~methacholine (mg) (geometric mean, 95% CI)                                    0.08 (0.03, 0.22)             0.10 (0.04, 0.25)
                                                                                                                    
  AUC salbutamol (%.time) (SD)                                                        412 (140)                     339 (201)
  Difference: paired t-test (95% CI)                                                  73 (-4, 149) p = 0.06         
  Difference: covariate analysis (placebo-formoterol) (least squares means, 95% CI)   63 (22, 105) p = 0.008        
                                                                                                                    
  Post-salbutamol FEV~1~at 20 mins (L) (SD)                                           2.79 (0.86)                   2.67 (0.84)
  Difference: paired t-test (95% CI)                                                  0.12 (0.03, 0.20) p = 0.008   
  Difference: covariate analysis (placebo-formoterol) (least squares means, 95% CI)   0.12 (0.06, 0.19) p = 0.003   

The salbutamol response, expressed as area under the curve, was 15% lower in the formoterol period compared to placebo (95% confidence interval 5 to 25%). This was a significant difference when taking the covariates into account (p = 0.008) (table [2](#T2){ref-type="table"}, figure [1](#F1){ref-type="fig"}).
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The final FEV~1~20 minutes after challenge after 5 mg salbutamol was 2.67 L in the formoterol arm compared to 2.79 L after placebo (95% CI for difference 0.06 to 0.19 L; p = 0.003).

Study 2: Ipratropium bromide
----------------------------

Thirteen subjects were recruited to the study. Two subjects withdrew during the first treatment period, one with uncontrolled asthma and one with a respiratory infection (taking formoterol and placebo respectively). Baseline characteristics are shown in table [1](#T1){ref-type="table"}. There was no effect of order of treatment.

The mean pre-challenge FEV~1~and PD~20~saline did not change significantly between formoterol and placebo arms. However, one subject experienced a less than 15% fall in FEV~1~with inhalation of saline after taking formoterol. For analytical purposes, the PD~20~saline for these challenges has been assumed to be 30 ml (the maximum value available for inhalation). Exclusion of this subject from analysis does not materially alter the results.

The response to ipratropium, expressed as the AUC, was not significantly different between formoterol or placebo treatment arms (table [3](#T3){ref-type="table"}, figure [2](#F2){ref-type="fig"}). The final FEV~1~, 30 minutes after ipratropium was not significantly different between the formoterol or placebo arms.

###### 

Results of the ipratropium study (study 2)

  Bronchodilator                                                                     Ipratropium                    Salbutamol                                       
  ---------------------------------------------------------------------------------- ------------------------------ ------------------------------ ----------------- -----------------
  Treatment                                                                          Placebo                        Formoterol                     Placebo           Formoterol
                                                                                                                                                                     
  Pre-challenge FEV~1~(L) (SD)                                                       2.77 (0.50)                    2.67 (0.41)                    2.62 (0.50)       2.67 (0.63)
  Post-challenge FEV~1~(L)(SD)                                                       2.15 (0.38)                    2.07 (0.37)                    2.06 (0.41)       2.11 (0.60)
  PD~20~saline (ml) (95% CI)                                                         11.8 (7.4--19)                 8.0 (4.6--13.8)                8.9 (4.9--16.0)   8.6 (5.0--14.6)
                                                                                                                                                                     
  AUC %.time (SD)                                                                    447 (215)                      401 (154)                      759 (203)         557 (131)
  Difference: paired t-test (95% CI)                                                 138 (-48,138) p = 0.303        202 (66, 339) p = 0.008                          
  Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI)   88 (-31, 207) p = 0.126        202 (42, 362) p = 0.019                          
                                                                                                                                                                     
  FEV~1~at 30 mins (L) (SD)                                                          2.81 (0.54)                    2.67 (0.45)                    2.91 (0.56)       2.74 (0.64)
  Difference: paired t-test (95% CI)                                                 0.22 (0--0.30) p = 0.056       0.10 (-0.05, 0.39) p = 0.117                     
  Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI)   0.11 (-0.06, 0.28) p = 0.172   0.22 (0.05, 0.38) p = 0.015                      
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The response to salbutamol was reduced in the formoterol arm compared to placebo. The mean difference in the AUC was 26% (95% CI 6 to 46%; p = 0.02) (table [3](#T3){ref-type="table"}, figure [2](#F2){ref-type="fig"}). The FEV~1~30 minutes after salbutamol was also lower in the formoterol arm compared to placebo, 2.74 L compared to 2.91 L (95% CI for difference 0.05 to 0.38; p = 0.02 by covariate analysis).

Discussion
==========

These studies confirm that the response to salbutamol is reduced in subjects taking long-acting beta-agonists. This reduction in response was evident even when 5 mg salbutamol was given via nebuliser. By contrast, the bronchodilator response to ipratropium was not affected by prior use of formoterol.

It is known that tolerance to bronchodilation occurs following regular formoterol. This has usually been demonstrated by measuring the bronchodilator response to up to 400 μg of salbutamol via metered dose inhaler. In terms of bronchodilation, 2.5 mg via a nebuliser is equivalent to 800 μg via metered dose inhaler and spacer \[[@B22]\]. We used a 5 mg dose of nebulised salbutamol in this study as this is commonly used in the emergency treatment of asthma. Higher single doses of salbutamol in a nebuliser are not recommended \[[@B2]\]. We found that the response to 5 mg of salbutamol was impaired after 1 week of regular formoterol use, indicating that patients using long-acting beta-agonists are likely to respond poorly to first-line treatment of acute severe asthma even if high doses of nebulised beta-agonist are used. Although the differences in the dose-response curves and final FEV~1~shown in this study may appear modest, it has been shown that the degree of beta-agonist tolerance increases with the degree of bronchoconstriction \[[@B7]\]. Patients with acute severe asthma will have much more severe bronchoconstriction than the 20% fall in FEV~1~induced in this study \[[@B2],[@B23]\]. They are therefore likely to have a much greater impairment in response to beta-agonists. In practice, many patients are given repeated doses of beta-agonists via nebuliser during an acute exacerbation. It was not possible to test the effects of repeated nebulisations using this model owing to the time taken for nebulisation (around 5 minutes) and the effect of spontaneous recovery from methacholine-induced bronchoconstriction.

The findings of the salbutamol study appear to contrast with those of a study which found no difference in the response to emergency department beta-agonist treatment between patients who had been taking long-acting beta-agonists and those who had not \[[@B24]\]. However, this emergency department study did not assess the preceding use of short-acting beta-agonists. Since almost all asthmatics take large doses of beta-agonists before presenting to hospital \[[@B25]\] and tolerance to beta-agonists develops rapidly \[[@B11]\], it is highly likely that the \'control\' group had also developed tolerance.

The bronchodilator response to ipratropium bromide was not impaired by prior use of long-acting beta-agonist. This confirms that the effect that we have interpreted as beta-agonist tolerance is specific to beta-agonists and unlikely to be due to a non-specific change in airway smooth muscle responsiveness. The intracellular effects of both beta-agonists and cholinergic agents are now known to be far more complex than action on single second messenger systems and there are plausible mechanisms of interaction between them \[[@B16],[@B26]\]. Muscarinic agonists appear to reduce the potency of beta-agonist bronchodilation, possibly through an effect on adenylyl cyclase \[[@B17]\]. The converse effect of muscarinic antagonists has been more difficult to assess \[[@B27]\]. Acetylcholine in human airways acts via muscarinic receptors to decrease cyclic AMP and reduce intracellular calcium release, thereby causing bronchoconstriction. Ipratropium blocks these actions, thereby reducing smooth muscle tone and causing bronchodilation. Cyclic AMP is also a key second-messenger in the response to beta-receptor activation. Regular exposure to beta-agonists appears to uncouple the beta-receptor from cAMP production \[[@B28]\]. Therefore it seemed possible that beta-agonist tolerance would also have an effect on the response to ipratropium. However, this was not discernible in our study. The addition of ipratropium bromide to beta-agonist treatment in acute severe asthma improves bronchodilation \[[@B15]\], whereas it affords little additional benefit in stable asthma \[[@B29]\]. It is possible that this is because the response to beta-agonist in severe asthma is impaired because of prior beta-agonist treatment, whereas the response to anticholinergic treatment is maintained. In this study the bronchodilator response to salbutamol was more rapid and greater than to ipratropium bromide, even after tolerance had developed. However, the effect of beta-agonist tolerance increases with increasing levels of bronchoconstriction \[[@B7]\]. In severe asthma the modest response to ipratropium bromide may become more important.

These studies used formoterol as the long-acting beta-agonist. Studies in the emergency department have focussed on patients taking salmeterol \[[@B24]\]. Salmeterol is a partial agonist at the beta-receptor compared to formoterol and theoretically it may be less likely to induce tolerance. Alternatively, salmeterol could act as a partial antagonist to salbutamol and reduce the effects of salbutamol still further. In practice, trials that have compared bronchodilator tolerance using the challenge-rescue model have not found any difference between salmeterol and formoterol \[[@B8],[@B10]\].

We have interpreted the reduction in response to beta-agonists as tolerance or tachyphylaxis to the effects of beta-agonists. Downregulation of the beta-receptors both in terms of receptor number and intracellular response to receptor stimulation is a pharmacologically predictable effect of repeated receptor stimulation \[[@B28]\]. An alternative explanation for the reduced response to beta-agonist is that some beta-receptors were still occupied by formoterol molecules at the time of the test and were therefore not available to bind to salbutamol, reducing its effect. We measured the bronchodilator response 36 hours after the last dose of formoterol. This is outside the normal duration of action of formoterol \[[@B30]\] and receptor occupancy should be minimal at this time. The 36-hour withdrawal of formoterol also minimises confounding of the results by large changes in pre-challenge FEV~1~and PD~20~. Although one subject showed a bronchoprotective effect at this time, overall there were no significant differences in the pre-challenge FEV~1~or PD~20~values. However, it is also known that beta-receptors recover rapidly following downregulation \[[@B31]\] and the timing of challenges 36 hours after the last dose of long-acting beta-agonist may mean that the tolerance measured in these trials was actually lower than that experienced by patients who continue take their long-acting beta-agonists twice daily \[[@B12]\].

There are potential limitations to our study design. First, this challenge-rescue model does not accurately reflect all of the pathophysiology of acute asthma, where airway inflammation, oedema and mucus production play important roles in airway obstruction. Nevertheless, airway smooth muscle contraction is important and is the main target of emergency bronchodilator treatment. In addition, not all of the subjects in these studies were taking inhaled corticosteroids, whereas current guidelines recommend that long-acting beta-agonists are used in conjunction with inhaled corticosteroids \[[@B1],[@B2]\]. There is conflicting evidence on whether systemic corticosteroids may partly reverse tolerance \[[@B32]\]. However, it is known that stable doses of inhaled corticosteroids do not influence the development of tolerance \[[@B5]\] and hence the use of inhaled corticosteroids was not a requirement in our selection of subjects.

This study is the first to demonstrate that beta-agonist bronchodilator tolerance can be demonstrated using hypertonic saline. Most previous studies using the \'challenge-rescue\' technique have used methacholine as the challenge agent \[[@B5]-[@B8],[@B10]-[@B12],[@B33]\]. This would have been inappropriate prior to studying the response to the anticholinergic drug ipratropium. Our findings confirm that the challenge-rescue model for studying bronchodilator tolerance works with both direct and indirect challenges. The bronchial response to hypertonic saline challenge is closely correlated with the response to exercise challenge \[[@B34]\]. A suboptimal response to salbutamol after exercise challenge has also been found when patients use regular beta-agonists \[[@B9]\].

Conclusion
==========

In summary, these studies confirm that beta-agonist bronchodilator tolerance develops during long-acting beta-agonist treatment. This is not overcome by 5 mg of nebulised salbutamol. The effect is specific to beta-agonists and does not affect the response to ipratropium bromide. Patients using long-acting beta-agonists may respond less well to emergency beta-agonist treatment. Additional treatment with an alternative bronchodilator should be considered early in the course of an exacerbation.
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AUC -- area under the curve

FEV~1~-- forced expiratory volume in one second
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